Document is current
Any future updates will be listed below
-
Authors
Ma, Ning https://orcid.org/0000-0003-4653-7797
Bhattacharya, Supriyo https://orcid.org/0000-0003-0483-2149
Muk, Sanychen
Jandova, Zuzana
Schmalhorst, Philipp S. https://orcid.org/0000-0002-5795-0133
Ghosh, Soumadwip
Le, Keith
Diers, Emelyne
Trainor, Nicole https://orcid.org/0000-0002-3758-9969
Farnaby, William https://orcid.org/0000-0001-8610-932X
Roy, Michael J. https://orcid.org/0000-0003-0198-9108
Kofink, Christiane https://orcid.org/0000-0003-2515-8843
Greb, Peter https://orcid.org/0000-0002-6757-4370
Weinstabl, Harald https://orcid.org/0000-0003-1308-2730
Ciulli, Alessio https://orcid.org/0000-0002-8654-1670
Bader, Gerd https://orcid.org/0000-0002-8410-3415
Sankar, Kyra
Bergner, Andreas https://orcid.org/0000-0002-5843-4325
Vaidehi, Nagarajan https://orcid.org/0000-0001-8100-8132
-
Funding
Funding for this research was provided by:
Boehringer Ingelheim
- License Information
-
More Information
Article History
Received: 12 December 2024
Accepted: 25 August 2025
First Online: 29 September 2025
Competing interests
: A.C. is a scientific founder and shareholder of Amphista Therapeutics, a company that is developing targeted protein degradation therapeutic platforms. The Ciulli laboratory receives or has received sponsored research support from Almirall, Amgen, Amphista Therapeutics, Boehringer Ingelheim, Eisai, Merck KaaG, Nurix Therapeutics, Ono Pharmaceutical, and Tocris-Biotechne. Z.J., P.S., C.K., P.G., H.W., G.B., and A.B. are current employees of Boehringer Ingelheim. E.D. is now an employee of AstraZeneca. All other authors declare that they have no competing interests.
